• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    More On CYCCP

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Cyclacel Pharmaceuticals, Inc. (CYCCP)

    -NasdaqCM
    4.21 Down 0.19(4.32%) Apr 29, 11:49AM EDT
    ProfileGet Profile for:
    Cyclacel Pharmaceuticals, Inc.
    200 Connell Drive
    Suite 1500
    Berkeley Heights, NJ 07922
    United States - Map
    Phone: 908-517-7330
    Fax: 866-271-3466
    Website: http://www.cyclacel.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:18

    Business Summary 

    Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cyclacel Pharmaceuticals, Inc.

    Key Executives 
     PayExercised
    Mr. Spiro George Rombotis , 57
    Chief Exec. Officer, Pres and Exec. Director
    745.00K0.00
    Mr. Paul McBarron , 55
    Chief Financial Officer, Chief Operating Officer, Exec. VP of Fin., Sec. and Exec. Director
    453.00K0.00
    Dr. Judy H. Chiao M.D., 56
    VP Clinical Devel. and Regulatory Affairs
    464.00K0.00
    Prof. David Glover Ph.D., FRS FRSE, 68
    Chief Scientist
    N/AN/A
    Dr. Susan Davis Ph.D.,
    Director of Bus. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.